Core Viewpoint - The approval of clinical trial for DR10624 injection by NMPA marks a significant advancement in the drug development process for Zhejiang Daor Bio, enhancing the company's competitiveness in the endocrine treatment field [1][4]. Drug Information - Drug Name: DR10624 injection - IND Acceptance Number: CXSL2501013 - Indication: Hypertriglyceridemia (HTG) - Applicant: Zhejiang Daor Bio - Conclusion: The clinical trial application for DR10624 injection has been approved to conduct trials for HTG [1][2]. R&D and Registration Status - DR10624 is a first-in-class long-acting tri-specific agonist targeting FGF21R, GCGR, and GLP-1R, developed independently by Daor Bio [2]. - The drug has successfully completed Phase II clinical studies for severe hypertriglyceridemia (sHTG) with positive topline results, showing a maximum liver fat reduction of 89% and over 70% relative reduction in triglycerides [3]. - The drug's Phase II clinical study results for sHTG were presented at AHA Scientific Sessions 2025, demonstrating significant reductions in triglyceride levels and liver fat content compared to placebo [3]. - DR10624 has also received approval for clinical trials in China for indications related to type 2 diabetes and weight management [3]. Impact on the Company - The approval of the clinical trial for DR10624 injection is a crucial step in the product's development, which is expected to enhance the company's core competitiveness in the endocrine treatment sector [4].

Group 1 - The core announcement is that Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., has received acceptance for the marketing authorization application of the innovative topical formulation, Roflumilast Cream 0.05%, aimed at treating mild to moderate atopic dermatitis in children aged 2-5 years [1] - The product is a result of a collaboration with Arcutis Biotherapeutics, Inc., signed in August 2023, and addresses a significant unmet clinical need in the pediatric population for safe and effective treatment options for atopic dermatitis [1] - The acceptance of the new drug application signifies a strategic entry into a clearly defined niche market with unmet needs, providing a new option for affected children and establishing a competitive edge for Huadong Medicine in the autoimmune disease sector [1] Group 2 - Autoimmune diseases are one of the three core therapeutic areas that Huadong Medicine is focusing on, with a strategy that includes both "introducing partnerships" and "independent innovation" to build a globally competitive product pipeline [2] - The company has a comprehensive range of existing and pipeline products targeting various conditions, including transplant immunity, psoriasis, atopic dermatitis, and rheumatoid arthritis, making it one of the more comprehensive pharmaceutical companies in the domestic autoimmune disease field [2]

Investment Rating - The industry investment rating for the pharmaceutical and biotechnology sector is "Hold" [2]. Core Insights - The report highlights significant advancements in the field of metabolic disorders, particularly focusing on the PCSK9 target and small nucleic acid therapies, driven by the increasing prevalence of dyslipidemia in China, which now affects over 400 million people [5][7]. - Novartis' innovative cholesterol-lowering drug, Leqvio (inclisiran), has received approval for a new indication in China, aimed at treating adult patients with primary hypercholesterolemia or mixed dyslipidemia, enhancing treatment adherence and long-term management of LDL-C levels [5][6]. Summary by Sections Industry Overview - The report discusses the acceleration of resource integration and the rapid development of brain-computer interface technologies, indicating a shift towards innovative treatment paradigms in the medical field [4]. Market Dynamics - The number of patients with dyslipidemia in China has significantly increased, with a notable rise in cases of hypercholesterolemia, particularly among younger populations [6]. - The report notes that the global clinical development pipeline for PCSK9-targeted therapies includes 55 projects, with a focus on monoclonal antibodies and emerging small nucleic acid drugs [6]. Investment Recommendations - The report suggests investors pay attention to companies such as Heng Rui Medicine, Innovent Biologics, and East China Pharmaceutical, which are positioned to benefit from advancements in the metabolic disorder treatment landscape [7].

Core Viewpoint - The article discusses the key deployments in the 2023 Central Document No. 1, focusing on agricultural modernization through technological innovation and the development of new productive forces in agriculture [5][6][7]. Group 1: Key Deployments in Agricultural Technology Innovation - The document emphasizes strengthening integrated innovation by enhancing the overall effectiveness of the agricultural technology innovation system, promoting enterprise-led innovation, and focusing on key areas such as seeds and agricultural machinery [5]. - It highlights the expansion of application scenarios through modern information technology and biotechnology, showcasing the significant role of agricultural drones and artificial intelligence in transforming agricultural practices [6]. - The document stresses the importance of promoting the transformation of agricultural technology achievements to address practical issues faced by farmers, ensuring that innovations reach rural areas effectively [7]. Group 2: Agricultural Bio-Manufacturing Paths Worth Noting - The article identifies high-value utilization of agricultural by-products, such as straw, as a key focus, indicating a shift from mere utilization to profitable applications [8]. - It discusses the potential of synthetic biology to enhance agricultural productivity by producing essential proteins and bio-fertilizers, thereby reducing reliance on chemical fertilizers [10]. - The development of new agricultural applications, including biodegradable materials and bio-pesticides, is highlighted as a means to promote green transformation in agriculture [11]. Group 3: Market Overview of Agricultural Bio-Manufacturing - As of February 9, 2025, there are 161 companies in the A-share market related to the "synthetic biology" concept, with a total market value of approximately 1.69 trillion yuan, averaging 10.5 billion yuan per company [15]. - The agricultural bio-manufacturing sector includes around 20 companies focusing on areas such as animal vaccines and feed additives, indicating a gradual industrial application of synthetic biology in agriculture [17]. - Key companies in this sector are noted for their focus on replacing feed, plant breeding, bio-pesticides, and precision farming, showcasing the diverse applications of synthetic biology in agriculture [17].

Core Viewpoint - The company has received approval for clinical trials of its drug candidate DR10624, which targets hypertriglyceridemia (HTG) [1] Group 1 - The company's subsidiary, Zhejiang Daor Biotechnology Co., Ltd., has been granted the Clinical Trial Approval Notice by the National Medical Products Administration [1] - The approved clinical trial will allow the company to proceed with testing the efficacy and safety of DR10624 injection [1] - The indication for the drug candidate is specifically for high triglyceride levels in the blood [1]

Core Viewpoint - The company has received approval for a clinical trial of its drug candidate DR10624, which targets hypertriglyceridemia (HTG) [1] Group 1 - The company’s subsidiary, Zhejiang Daor Biotechnology Co., Ltd., has been granted a clinical trial approval notice by the National Medical Products Administration [1] - The approved clinical trial will allow the company to proceed with testing the efficacy and safety of DR10624 injection [1] - The indication for the clinical trial is specifically for high triglyceride levels in the blood [1]

证券代码：000963 证券简称：华东医药 公告编号：2026-004 华东医药股份有限公司 关于控股子公司获得药物临床试验批准通知书的公告 适应症：高甘油三酯血症（Hypertriglyceridemia，HTG） 申请事项：临床试验 申请人：浙江道尔生物科技有限公司 结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 2025 年 11 月 26 日受理的 DR10624 注射液临床试验申请符合药品注 册的有关要求，同意本品开展高甘油三酯血症的临床试验。 二、该药物研发及注册情况 DR10624 是道尔生物自主研发的全球首创（First-in-class）的靶 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华东医药股份有限公司（以下简称"公司"） 控股子公 司浙江道尔生物科技有限公司（以下简称"道尔生物"）收到国家药 品监督管理局（以下简称"NMPA"）核准签发的《药物临床试验批 准通知书》（通知书编号：2026LP00301），由道尔生物申报的 DR10624 注射液临床试验申请已获得批准，可以开展临床试验，适应症为高甘 油三酯血症（Hy ...

消息面上，近日，由脑机交互与人机共融海河实验室周鹏智慧中医团队牵头，天津中医药大学第一附属 医院、天津市滨海新区中医医院、天津中医药大学、天中依脉公司等多家优势单位联合研发的全国首个 脑控针灸融合神经康复装备平台"神工-华佗"落地。团队创新性研发了"脑机接口+智能穿戴式针灸"融合 技术，相关研究已获国家载人航天实验项目等多项前期项目支撑。 截至2026年2月4日 13:13，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，东阿阿胶领涨 3.35%，恩华药业上涨1.14%，康弘药业上涨1.03%；特宝生物领跌。医疗创新ETF(516820)最新报价0.36 元。 华金证券认为，政策端持续加码——国家药监局首次将"人工智能医疗器械"列为四大重点发展领域，技 术端DeepSeek-R1等开源大模型显著降低开发门槛，共同推动国内AI+医疗市场进入高速增长通道；全 球AI医疗市场规模预计2022–2030年CAGR达35.5%，至2030年将达1553亿美元。 从资金净流入方面来看，医疗创新ETF近13天获得连续资金净流入，最高单日获得4182.65万元净流 入，合计"吸金"2.46亿元，日均净流入达18 ...

截至2026年2月4日 10:58，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，东阿阿胶领涨 3.31%，恩华药业上涨1.62%，新和成上涨1.57%；特宝生物领跌。医疗创新ETF(516820)最新报价0.36 元。 从资金净流入方面来看，医疗创新ETF近13天获得连续资金净流入，最高单日获得4182.65万元净流 入，合计"吸金"2.46亿元，日均净流入达1890.95万元。（数据来源：Wind） 消息面上，阿斯利康宣布未来十年在中国投资150亿美元，重点投向细胞治疗与放射性偶联药物 （RDC）两大前沿方向，涵盖北京、上海的战略研发中心建设，以及无锡、泰州、青岛、北京等地生 产基地扩建与新建，并计划将中国高技能员工队伍扩展至超2万人。 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由投资人自行负担。基金的过 往业绩及其净值高低并不预示其未来业绩表现，基金管理人管理的其他基金的业绩不构成对本 ...

每经AI快讯，据华东医药（000963）官微2月4日消息，日前，华东医药全资子公司杭州中美华东制药 有限公司收到国家药品监督管理局(NMPA)签发的《受理通知书》，罗氟司特乳膏(ZORYVE)0.05%上市 许可申请获得受理，申报适应症为：适用于2岁至5岁轻度至中度特应性皮炎患者的局部外用治疗。 ...